Drugs /

pf-07104091

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, CDK2 inhibitor PF-07104091 selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are frequently overexpressed in tumor cells. CDK2/cyclin E complex plays an important role in retinoblastoma (Rb) protein phosphorylation and the G1-S phase cell cycle transition. CDK2/cyclin A complex plays an important role in DNA synthesis in S phase and the activation of CDK1/cyclin B for the G2-M phase cell cycle transition.

Clinical Trials

View Clinical Trials for pf-07104091

Pf-07104091 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating pf-07104091, 1 is phase 2 (1 open).

HER2 Deficient Expression and HER2 Negative are the most frequent biomarker inclusion criteria for pf-07104091 clinical trials.

Breast carcinoma, fallopian tube carcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in pf-07104091 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pf-07104091
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pf-07104091 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cyclin-dependent kinase 2 inhibitor pf-07104091, pf 07104091, pf07104091, cdk2 inhibitor pf-07104091
Drug Target(s) [2]:
CDK2
NCIT ID [1]:
C175251

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.